Key result
Taxane exposure linked to ~1050% increased risk of chemotherapy-induced anemia.
Why the study?
What are the predictive factors for anemia induced by chemotherapy in early breast cancer patients?
Cohort (n=378)
No
What are the predictive factors for anemia induced by chemotherapy in early breast cancer patients?
Hazard Ratio: 11.5 (95% CI 2.5–52.6)
Exposure to taxanes, high-dose anthracyclines, lower baseline hemoglobin, mastectomy, older age, and lower BMI are significant risk factors for chemotherapy-induced anemia in early breast cancer.
Identifies candidate baseline predictors of chemo-induced anemia; leaves open whether these warrant prospective validation or supportive-care trials.
BACKGROUND: The study's objective was to assess the predictive factors of anemia induced by chemotherapy in early breast cancer patients. PATIENTS AND METHODS: Patients treated by adjuvant or neo-adjuvant anthracyclin-based regimens with or without taxanes between 1998 and 2006 in a French university hospital were studied. Chemotherapy included. Anemia was defined as a hemoglobin (Hb) concentration lower than 12 g/dL. Multivariate analysis by logistic regression was used to search for baseline risk factors linked to the occurrence of anemia. RESULTS: Among 378 patients, anemia was observed in 64% of cases. The occurrence of anemia was significantly related to 6 risk factors: exposure to taxanes (HR 11.5, 95% CI, 2.5-52.6), high dose of anthracyclin (epirubicin 100 mg/m²)(HR 4.3; 95% CI, 2.8-8), Hb at baseline < 13.5 g/d (HR 4.3; 95% CI, 2.6-7.1), mastectomy (HR 2.5; 95% CI, 1.4-3.3), age >60 (HR 2.5; 95% CI, 1.4-5) years old (HR 2.5; 95% CI, 1.4-5) and Body Mass Index (BMI) ≤ 25 kg/m² (HR 1.7; 95% CI, 1.0-2.8). CONCLUSION: Taking into account the following factors: type of chemotherapy, BMI, age, Hb at baseline should allow a better identification of patients at risk of anemia.
No takes yet. Share an insight, caveat, or question.
Chaumard et al. (2011) conducted a cohort in early breast cancer (n=378). Exposure to taxanes vs. No taxane exposure was evaluated on Anemia (hemoglobin < 12 g/dL) (HR 11.5, 95% CI 2.5-52.6). Exposure to taxanes (HR 11.5; 95% CI 2.5-52.6), high-dose anthracyclin, low baseline hemoglobin, mastectomy, age >60, and BMI ≤25 kg/m² significantly increased the risk of chemotherapy-induced anemia.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: